Search - tctmd.com

Displaying 401 - 420 of 482

Sort: Relevancy | Date

News Industry News

4C Medical Exceeds $8 Million Convertible Note Financing Round Led by Anges Québec

July 20, 2017

News Industry News

4C Medical's Novel Mitral Regurgitation Therapy Highlighted at TVT Innovation Forum

June 16, 2017

News Conference News TVT 2017

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

Michael O'Riordan

June 15, 2017

News Industry News

4C Medical's Mitral Regurgitation Therapy to be Featured in 2017 TVT Innovation Forum

June 08, 2017

News Conference News EuroPCR 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

Michael O'Riordan

May 24, 2017

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

Shelley Wood

May 18, 2017

News Daily News

‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry

Todd Neale

May 17, 2017

Presentation SCAI 2017

Results From The BRAVO 3 Randomized Trial

Presenter: Usman Baber

May 15, 2017

News Conference News SCAI 2017

New-Onset A-fib After TAVR Linked to Increased Risk of Early Stroke

L.A. McKeown

May 12, 2017

Presentation SWVS 2017

Atrial Fibrillation After SAVR: Optimizing management of peri-TAVR AF

Presenter: Ankur Kalra

May 06, 2017

News Conference News ACC 2017

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

L.A. McKeown

March 21, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

Shelley Wood

March 19, 2017

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

Todd Neale

March 15, 2017

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

Todd Neale

March 14, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

Presentation CRT 2017

Triple Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement

Presenter: Chadi Alraies

February 22, 2017

Presentation JIM 2017

Appendix Closure is the Solution

Presenter: Horst Sievert

February 10, 2017

News Features

The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol

Michael O'Riordan

January 24, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

Presentation

Apixaban in Patients With Atrial Fibrillation After TAVR

Presenter: J. Seeger

January 03, 2017

Advertisement

4C Medical Exceeds $8 Million Convertible Note Financing Round Led by Anges Québec

4C Medical's Novel Mitral Regurgitation Therapy Highlighted at TVT Innovation Forum

Embolic Protection During TAVR Reduces Stroke Risk, Single-Center Study Shows

4C Medical's Mitral Regurgitation Therapy to be Featured in 2017 TVT Innovation Forum

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

More Early Stroke With SAVR Than TAVR in SURTAVI

‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry

Results From The BRAVO 3 Randomized Trial

New-Onset A-fib After TAVR Linked to Increased Risk of Early Stroke

Atrial Fibrillation After SAVR: Optimizing management of peri-TAVR AF

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

Live From Washington: ACC 2017, Day Three

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Triple Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement

Appendix Closure is the Solution

The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Apixaban in Patients With Atrial Fibrillation After TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content